Advertisement

Related Videos

Welcome and Introduction to Vi3C

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Feb
03
Today In Oncology
Deep Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
Head and Neck Cancer How Does Genetic Ancestry Impact Tumor Genomics
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo